Institution Directory

Clinical trials at Beth Israel Deaconess Medical Center

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

621

Shown on this page

Current sort

Live official records

Conditions: Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone
Interventions: Hydrocortisone, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Long COVID, Post-Acute Sequelae of COVID-19, COVID Long-Haul
Interventions: Mind Body Intervention #1; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Unresectable Hepatocellular Carcinoma
Interventions: Atezolizumab, Bevacizumab, Stereotactic body radiation therapy (SBRT); Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Myasthenia Gravis
Interventions: efgartigimod; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 17
States / cities: San Francisco, California • Boca Raton, Florida • Jacksonville Beach, Florida + 12 more

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: Venetoclax, Obinutuzumab, Acalabrutinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Stamford, Connecticut • Boston, Massachusetts • Providence, Rhode Island

Conditions: Hidradenitis Suppurativa
Interventions: Lutikizumab, Placebo; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more

Conditions: Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi], Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan; Drug · Diagnostic Test
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 40 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Interventions: SGR-1505; Drug
Lead sponsor: Schrödinger, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more

Conditions: Relapsed and Refractory Multiple Myeloma
Interventions: anitocabtagene-autoleucel; Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Milwaukee, Wisconsin

Conditions: Atrial Fibrillation, Stroke, Bleeding
Interventions: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Non-Vitamin K Oral Antagonists; Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 79
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more

Conditions: Breast Cancer
Interventions: Gedatolisib, Palbociclib, Fulvestrant, Alpelisib; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older
Enrollment: 701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 71
States / cities: Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 62 more

Conditions: Pacemaker, Implantable Defibrillator
Interventions: Alert-based care, Guideline-based Care; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

About this Beth Israel Deaconess Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Beth Israel Deaconess Medical Center in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Beth Israel Deaconess Medical Center

Filter and sort this campus

Live official records

Corticosteroids to Treat Pancreatitis

Mind Body Intervention for Long COVID-19

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Study of SGR-1505 in Mature B-Cell Neoplasms

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Amplatzer Amulet LAAO vs. NOAC

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase)

About this Beth Israel Deaconess Medical Center institution page